|
1
|
Myonecrosis after revascularization procedures.
|
J Am Coll Cardiol
|
1998
|
2.11
|
|
2
|
Comparison of the ABC/2 estimation technique to computer-assisted volumetric analysis of intraparenchymal and subdural hematomas complicating the GUSTO-1 trial.
|
Stroke
|
1998
|
2.03
|
|
3
|
Geographic variability in outcomes within an international trial of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes. Results from PURSUIT.
|
Eur Heart J
|
2000
|
1.62
|
|
4
|
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
|
Eur Heart J
|
2004
|
1.59
|
|
5
|
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation.
|
Heart
|
2008
|
1.54
|
|
6
|
Does the discharge ECG provide additional prognostic insight(s) in non-ST elevation ACS patients from that acquired on admission?
|
Eur Heart J
|
2003
|
1.40
|
|
7
|
Shifting the open-artery hypothesis downstream: the quest for optimal reperfusion.
|
J Am Coll Cardiol
|
2001
|
1.22
|
|
8
|
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II.
|
J Am Coll Cardiol
|
1999
|
1.11
|
|
9
|
Thrombolysis-related intracranial hemorrhage: a radiographic analysis of 244 cases from the GUSTO-1 trial with clinical correlation. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries.
|
Stroke
|
1998
|
1.08
|
|
10
|
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage.
|
Circulation
|
1998
|
0.98
|
|
11
|
A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: the ATLAST trial.
|
J Am Coll Cardiol
|
2001
|
0.96
|
|
12
|
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes.
|
Circulation
|
2000
|
0.92
|
|
13
|
Population pharmacokinetics and pharmacodynamics of rivaroxaban in patients with non-valvular atrial fibrillation: results from ROCKET AF.
|
J Clin Pharmacol
|
2014
|
0.91
|
|
14
|
Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention.
|
J Invasive Cardiol
|
2000
|
0.84
|
|
15
|
Atrial fibrillation and mortality among patients with acute coronary syndromes without ST-segment elevation: results from the PURSUIT trial.
|
Am J Cardiol
|
2001
|
0.84
|
|
16
|
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation. PURSUIT Steering Committee. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
|
JAMA
|
2000
|
0.83
|
|
17
|
Initial risk stratification and presenting characteristics of patients with evolving myocardial infarctions.
|
Emerg Med J
|
2008
|
0.83
|
|
18
|
Effects of stroke on medical resource use and costs in acute myocardial infarction. GUSTO I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries Study.
|
Circulation
|
1999
|
0.82
|
|
19
|
Cardiac enzyme elevations after cardiac surgery: the cardiologist's perspective.
|
Am Heart J
|
2001
|
0.77
|
|
20
|
Danazol increases the anticoagulant effect of warfarin.
|
Ann Pharmacother
|
1992
|
0.76
|
|
21
|
The use of tomographic myocardial perfusion scanning to evaluate an electrocardiographic salvage estimation method in patients with acute myocardial infarction: an AMISTAD substudy. Acute Myocardial Infarction Study Adenosine.
|
J Electrocardiol
|
1999
|
0.75
|